Written in Blood
(conducted in 147 evaluable patients),
only TP53 mutations remained statisti-
cally significantly associated with poorer
OS and PFS:
• hazard ratio (HR) for PFS = 6.2
(95% CI 2.6-14.9; p<0.0001)
• HR for OS = 6.8 (95% CI 3.3-14.5;
p<0.001)
Combined MIPI (MIPI-c) high-risk
(defined as high-risk MIPI with Ki67
expression) was also significantly
associated with poorer PFS and cumula-
tive incidence of relapse (CIR; HR=2.2;
95% CI 1.2-4.0; p=0.01 for PFS and
HR=2.6; 95% CI 1.4-4.9; p=0.003
for CIR).
When the authors compared out-
comes between patients with (n=20) and
without (n=156) TP53 mutations, they
confirmed the poor prognosis conferred
by TP53 mutations:
• median OS: 1.8 years vs. not
reached (p<0.001)
• median PFS: 0.9 years vs. 10.2 years
(p<0.001)
• median time to relapse: 1.0 year vs.
12.3 years (p>0.001)